ArticleChinese medicine2010
A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906.
Article in Chinese medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Cancer chemotherapy and pharmacology · 2014Trial
- Construction and application of a precise evaluation method for the quality of traditional Chinese medicine based on "target-combined quality evaluation" using safflower as an example.Frontiers in pharmacology · 2025Article
- The effective combination therapies with irinotecan for colorectal cancer.Frontiers in pharmacology · 2024Review
- Detecting and Profiling of Milk Thistle Metabolites in Food Supplements: A Safety-Oriented Approach by Advanced Analytics.Metabolites · 2023Review
- YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity.Frontiers in pharmacology · 2022Article
- YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.Scientific reports · 2021Article
- Multifaceted Factors Causing Conflicting Outcomes in Herb-Drug Interactions.Pharmaceutics · 2020Review
- Herbal pair Huangqin-Baishao: mechanisms underlying inflammatory bowel disease by combined system pharmacology and cell experiment approach.BMC complementary medicine and therapies · 2020Article
- Recent advances of novel technologies for quality consistency assessment of natural herbal medicines and preparations.Chinese medicine · 2020Review
- Cancer Biomarkers for Integrative Oncology.Current oncology reports · 2019Review
- Herbal Medicines for Irinotecan-Induced Diarrhea.Frontiers in pharmacology · 2019Review
- Article
- Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway.Cell communication and signaling : CCS · 2018Article
- Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906).Frontiers in pharmacology · 2018Article
- Anticancer drug discovery from Chinese medicinal herbs.Chinese medicine · 2018Review
- Systems Pharmacology Based Strategy for Q-Markers Discovery of HuangQin Decoction to Attenuate Intestinal Damage.Frontiers in pharmacology · 2018Article
- Application of Metabolomics to Quality Control of Natural Product Derived Medicines.Biomolecules & therapeutics · 2017Review
- A multiple biomarker assay for quality assessment of botanical drugs using a versatile microfluidic chip.Scientific reports · 2017Article
- Gut microbiota drives the attenuation of dextran sulphate sodium-induced colitis by Huangqin decoction.Oncotarget · 2017Article
- Approaches to establish Q-markers for the quality standards of traditional Chinese medicines.Acta pharmaceutica Sinica. B · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEstablishing botanical extracts as globally-accepted polychemical medicines and a new paradigm for disease treatment, requires the development of high-level quality control metrics. Based on comprehensive chemical and biological fingerprints correlated with pharmacology, we propose a general approach called PhytomicsQC to botanical quality control.
methodsIncorporating the state-of-the-art analytical methodologies, PhytomicsQC was employed in this study and included the use of liquid chromatography/mass spectrometry (LC/MS) for chemical characterization and chemical fingerprinting, differential cellular gene expression for bioresponse fingerprinting and animal pharmacology for in vivo validation. A statistical pattern comparison method, Phytomics Similarity Index (PSI), based on intensities and intensity ratios, was used to determine the similarity of the chemical and bioresponse fingerprints among different manufactured batches.
resultsEighteen batch samples of Huangqin Tang (HQT) and its pharmaceutical grade version (PHY906) were analyzed using the PhytomicsQC platform analysis. Comparative analysis of the batch samples with a clinically tested standardized batch obtained values of PSI similarity between 0.67 and 0.99.
conclusionWith rigorous quality control using analytically sensitive and comprehensive chemical and biological fingerprinting, botanical formulations manufactured under standardized manufacturing protocols can produce highly consistent batches of products.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.